Loading...
Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection.
Cornberg, Markus Manns, Michael P
Cornberg, Markus
Manns, Michael P
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2017-01
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 159.13 KB
Loading...
figure 1
Adobe PDF, 82.72 KB
Other Titles
Abstract
Despite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.
Citation
Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. 2017, 37 Suppl 1:67-72 Liver Int.
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1478-3231